Yailian et al., [1] describe the medical and pharmaceutical staff perspectives of pharmacist's interventions in a clinical rheumatology setting in France. Interventions were classified according to a classification system that denoted drug-related problems (e.g. untreated indication) and the types of intervention thereafter (e.g. drug switch). A scale was used that categorised the potential clinical impact as minor, significant, major, critical or catastrophic. On evaluating the scale, there was found to be agreement between the rheumatologist and pharmacist in terms of clinical relevance for about half the items rated.
